Genmab Reports New Epcoritamab Data, 93% ORR in Elderly DLBCL Patients
Genmab announced new data from two studies evaluating epcoritamab. Results from the Phase 2 EPCORE DLBCL-3 study showed an overall response rate, ORR, of 67% and a complete response rate of 58% with epcoritamab monotherapy in elderly patients with newly diagnosed DLBCL. In the Phase 1b/2 EPCORE NHL-2 study, epcoritamab plus rituximab plus dose-attenuated cyclophosphamide, doxorubicin, vincristine, and prednisone demonstrated an ORR of 93% and a CR rate of 86% in elderly patients with newly diagnosed DLBCL.
